Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:01:40 EDT Thu 22 May 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for U:PHIO from 2024-05-23 to 2025-05-22 - 51 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2025-05-19 07:46U:PHIONews ReleasePhio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference
2025-05-15 16:16U:PHIONews ReleasePhio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
2025-05-07 07:47U:PHIONews ReleasePhio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
2025-05-01 07:46U:PHIONews ReleasePhio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
2025-04-09 07:46U:PHIONews ReleasePhio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort
2025-04-03 07:46U:PHIONews ReleasePhio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894
2025-03-31 16:02U:PHIONews ReleasePhio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update
2025-03-10 07:46U:PHIONews ReleaseAmerican Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting
2025-03-05 07:46U:PHIONews ReleasePhio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study
2025-02-26 07:46U:PHIONews ReleasePhio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
2025-02-20 07:48U:PHIONews ReleasePhio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors
2025-02-03 07:46U:PHIONews ReleasePhio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
2025-01-22 07:02U:PHIONews ReleasePhio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
2025-01-21 16:16U:PHIONews ReleasePhio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2025-01-16 13:01U:PHIONews ReleasePhio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2025-01-15 07:01U:PHIONews ReleasePhio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2025-01-14 07:01U:PHIONews ReleasePhio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2025-01-13 07:46U:PHIONews ReleasePhio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762
2025-01-02 07:46U:PHIONews ReleasePhio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology
2024-12-23 13:16U:PHIONews ReleasePhio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2024-12-19 14:29U:PHIONews ReleasePhio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2024-12-19 07:46U:PHIONews ReleasePhio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762
2024-12-12 09:22U:PHIONews ReleasePhio Pharmaceuticals Announces Publication in Frontiers in Immunology
2024-12-10 07:46U:PHIONews ReleasePhio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award
2024-12-03 07:46U:PHIONews ReleasePhio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
2024-11-19 07:46U:PHIONews ReleasePhio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study
2024-11-14 17:48U:PHIONews ReleasePhio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
2024-11-07 10:01U:PHIONews ReleasePhio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
2024-11-01 07:47U:PHIONews ReleasePhio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
2024-10-24 08:02U:PHIONews ReleasePhio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
2024-10-18 13:31U:PHIONews ReleaseCorrection to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
2024-10-18 08:01U:PHIONews ReleasePhio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series
2024-10-16 08:02U:PHIONews ReleasePhio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference
2024-10-07 08:02U:PHIONews ReleasePhio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells
2024-10-02 08:01U:PHIONews ReleasePhio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
2024-10-01 08:02U:PHIONews ReleasePhio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference
2024-09-25 08:02U:PHIONews ReleaseINTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society
2024-09-17 08:02U:PHIONews ReleasePhio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
2024-09-16 08:01U:PHIONews ReleasePhio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA
2024-09-09 07:01U:PHIONews ReleasePhio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
2024-08-29 08:31U:PHIONews ReleasePhio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
2024-08-14 17:01U:PHIONews ReleasePhio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
2024-08-06 08:01U:PHIONews ReleasePhio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound
2024-08-01 08:01U:PHIONews ReleasePhio Pharmaceuticals Announces New Chief Financial Officer
2024-07-12 08:01U:PHIONews ReleasePhio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds
2024-07-08 08:01U:PHIONews ReleasePhio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762
2024-07-05 08:01U:PHIONews ReleasePhio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds
2024-07-02 11:46U:PHIONews ReleasePhio Pharmaceuticals Announces Reverse Stock Split
2024-06-18 07:31U:PHIONews ReleasePhio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging
2024-05-28 07:31U:PHIONews ReleasePhio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762
2024-05-23 17:01U:PHIONews ReleasePhio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)